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Introduction 
A link between bone marrow and organ transplantation 
was provided when microchimerism was detected with 
sensitive immunocytochemical and polymerase chain 
reaction techniques in the tissues or blood of 30 human 
kidney or liver recipients studied from 2.5 to 30 years 
postoperatively [1,2]. The donor cells were multilineage, 
but paradoxically many appeared to be dendritic cells 
(DCs), a potent antigen-presenting cell [3]. Individual 
samples from patients often do not contain the donor 
leukocytes, which wax and wane [4]. However, dissemi-
nated donor cells including DCs, or alternatively donor 
DNA, are consistently demonstrable if rodents bearing 
long-term grafts are thoroughly studied [5-7]. 
Along with peripheral migration of the donor cells from a 
successfully transplanted graft, there is an influx of host 
leukocytes that do not cause graft damage [2]. Thus, both the 
allograft and recipient become genetic composites (Fig. 1a). 
A mirror image condition exists after bone marrow trans-
plantation [8] (Fig. 1b), proved by demonstrating a trace 
residual population of host leukocytes in essentially all stable 
human bone marrow recipients who previously were thought 
to have complete donor-cell chimerism [9]. 
Previous enigmas 
These discoveries have provided an important framework 
for a better understanding of allograft 'acceptance', for 
analysis of management problems, and for therapeutically 
oriented transplantation research [10-°]. In the new 
context of this two-way paradigm, the donor leukocytes 
in organ recipients constitute the small member of 
antagonistic but reciprocally attenuated or abrogated 
host-versus-graft (HVG) and graft-versus-host (GVH) 
arms, each of which can induce specific nonreactivity 
(tolerance) in the other [1,2,8] (Fig. 2). Deletion of the 
host arm by the cytoablation before bone marrow but not 
before organ transplantation alters the balance in this 
mutual interaction and is thus responsible for the 
disparities in the two different kinds of transplantation 
(Table O. 
The dynamic 'nullification' effect of the two arms makes it 
obvious why kidney recipients can sometimes stop 
immunosuppression without losing their allografts [10°°]. 
It also explains the poor prognostic value of human 
leukocyte antigen matching for organ transplantation, the 
rarity of GVH disease after the engraftment of immuno-
logically active organs such as the intestine and liver, and 
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Figure 1 
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Two-way paradigm with which transplan-
tation is seen as a bidirectional and 
mutually cancelling immune reaction that 
is (a) predominantly host-versus-graft 
(HVG) with whole organ grafts, and (b) 
predominantly graft-versus-host (GVH) 
with bone marrow grafts. 
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the characteristic cycle of immunologic crisis and resolu-
tion, first observed in kidney recipients [11], that was most 
practically monitored by serial changes in organ allograft 
function (Fig. 2). 
The two-way paradigm defines success and failure after 
transplantation in a different way than before. Success 
implies that chimerism has been introduced which mayor 
may not be immunosuppression-dependent. Failure con-
notes the therapeutically uncontrollable ascendency of 
HVG or GVH. Pathologic evidence of both processes is 
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frequently found in failed liver or intestinal transplant 
cases, but the ultimate result is predominantly rejection or 
GVH disease. In kidney recipients who are exposed to a 
small load of passenger leukocytes, findings in the 
recipient and allograft are essentially always interpreted 
in the context of rejection. 
The counter-argument 
In the previous conception of organ allograft acceptance, 
which excluded a role for lymphoid cell microchimerism, 
it was axiomatic that antigens of the parenchymal (or 
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Fig. 2 
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of each leukocyte population to the other 
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vascular endothelial) cells of transplanted organs per-
mitted or induced allograft acceptance [12] in various 
ways, for example via veto/suppressor cells, cytokine 
profile changes or enhancing antibodies. In an extension of 
such reasoning, it ha~ been contended that the micro-
chimerism associated with successful organ transplanta-
tion, and conversely its disappearance with or just after 
irreversible rejection in experimental models [5,7], is 
inconsistent and epiphenomenal [13]. 
Such arguments have been skilfully summarized in a 
debate format by Wood and Sachs [14"]. However, there is 
no crcdible evidence to support the contention [13,14"] 
that the microchimerism found in organ recipients is the 
effect rather than the cause of allograft acceptance. Failure 
with limited tissue or blood sampling to find peripheral 
microehimerism in patients after successful organ trans-
plantation connotes an incomplete search [15]. In our 
clinical studies [1,2] in which sampling was from multiple 
sites, the inconsistent yields from individual locations 
were comparable with those reported by others [14"]. 
However, when the results wcre pooled from the different 
sites in individual cases, all 30 of our originally tested 
patients had microchimerism. In rat experiments where 
tissues can be retrieved without limit, we have achicved a 
consistent association of chimerism with avoidance of 
chronic rejection [5-7,15]. 
Post-transplant Iymphoproliferative disorders 
The two-way paradigl.l also has shed light on the 
pathogenesis of post-transplant lymphoproliferative dis-
orders (PTLDs) [16""]. Except for their frequent Epstcin-
Barr virus (EBV) association, these human B-ceIl lympho-
mas are indistinguishable from those induced by Schwartz 
et al. [171 in a mouse chimerism model 3 years before the 
PTLD complication was first recognized clinically [18] 
and explained by loss of surveillance [19]. Rather than 
simple loss of surveillance, Schwartz et al. ascribed the 
experimental tumors to an active Iymphoproliferative 
Donor 
Time after transplantation 
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Table 1. Differences between conventional bone marrow and organ 
transplantation 
Bone Marrow 
------------_ .. - --------
Recipient cytoablation * 
MHC compatibility 
Principal complication 
Drug free state 
Term for success 
Yes 
Critical 
GVHD 
Common 
Tolerance 
Organ 
No 
Not critical 
Rejection 
Rare 
'Acceptance'" 
• All differences derive from this therapeutic step, which in effect 
establishes an unopposed graft-versus-host (GVH) reaction in the bone 
marrow recipient whose countervailing immune reaction is eliminated. 
"or 'operational tolerance'. GVHD, graft-versus-host disease; MHC, 
major histocompatibility complex. 
response bv the dominant immune apparatus to the 
persistent subclinical GVH counterattack of the minority 
donor leukocyte population. The relevance of his ob-
servations to clinical PTLDs could only be appreciated 30 
years later with the discoveries of microchimerism. 
Now, it could be seen that PTLD is a complication of the 
joint activation of the coexisting immune populations, to 
which the powerful cofactors of immune suppression and 
viral infection (particularly with EBV [20]) are added 
[16""]. BecausE~ host leukocytes in most organ recipients 
vastly outnumber the chimeric donor cells, with a similar 
obverse disproportion in successfully engrafted bone 
marrow recipients, clinical PTLDs are usually of recipient 
origin in the first instance and of donor phenotype in the 
second (summarized in [16""]). 
Heavy immunosuppression typically precedes the appear-
ance of the tumors in the human organ recipient. 
Conversely, reduction or discontinuance of the antirejec-
tion drugs [21] can allow restoration of immune surveil-
lance, manifested by PTLD regression. Tumor involution 
frequently is coincident with organ rejection, but in most 
cases a level of immune suppression can be reached by 
trial and error that permits salvage of the allograft without 
precipitating regrowth of the lymphoma [21-23]. 
This dissociation of lesion involution and rejection has 
suggested that the tumor destruction might be by an 
autologous immune reaction directed to a tumor-specific 
antige~ and that the target was an EBV -infected 
immunohlast, freed from T-cell sur\'eillance by immuno-
suppression [24-27]. However, this does not explain why 
the less common EBV- neoplasms also often frequently 
regn:ss ,,,hen immunosuppression is stopped [1600 ]. Thus, 
although viral cofactors, and especially EBV, arc undoubt-
edly involved in the development of PTLD, their role has 
not been fullY clarified. 
Neyertheless, frcsh insight about PTLD obtained so far 
can be used to map treatment strategies of cellular 
immune modulation as discllssed elsewhere [16··]. How 
ro prevent PTLD is also obvious. Because immune 
suppression is a dominant cofactor, particularly when it 
is '1 '-cell directed, it was not surprising to note an 
incremental increase in PTLD with successively more 
potent immunosuppressants [21,28,29]. The risk can be 
reduced at the outset by avoiding the joint use of the 
biologic anti lymphoid agents (i.e. ALG and OKT3) with 
cyclosporine and tacrolimus except as a last resort, and 
then with extreme caution. 
When P' fLO is diagnosed early in development, it is usually 
a trivial problem requiring only drug dose reduction. At the 
Children's Hospital of Pittsburgh, nine (13.2%) of 68 
recipients (of 69 kidney allografts) treated with tacrolimus-
based immune suppression between 1989 and 1995 deyel-
oped histopathologically verified PTLD [30·]. No deaths 
resulted, or any graft losses except from chronic rejection 3 
years later in one case. At the same institution, histopatho-
logically verified PTL D was diagnosed in 28 (12.1 %) of the 
232 consecutive primary liver recipients treated with 
tacrolimus bet\veen 1989 and 1995. Although five of the 28 
died of potentially PTLD-related complications, the 4-year 
patient and graft survival (82.2%) is essentially the same as in 
the 204 non-PTLD cases. 
Therapeutic implications 
Understanding the concept of the donor-recipient leuko-
cyte dialogue inherent in the two-way paradigm helps in 
predicting what can (and cannot) be accomplished with 
various tolerance-inducing strategies, all of ,vhich arc 
attempts to influence this immunologic interaction. 
Adjunct leukocyte infusion 
Historic efforts to improyc organ transplantation results 
with donor-specific blood transfusion [31] or donor bone 
marrow [32,33] were based on sound therapeutic princi-
ples involving the unrecognized augmentation of chimer-
ism. In an extension of these pioneer trials, our premise 
was that the spontaneous microchimerism of organ 
transplantation could be greatly augmented bv the co-
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administration of unmodified donor bone marrow cells 
without a significant risk of GVH disease, providing the 
two immllnocyte populations were initially competent and 
that immunosuppression was delivered to both equally. It 
also was predicted that the timing, se,'eritv, and frequency 
of acute rejection would be approximately the same as in 
non-marrow augmented control patients [1,34,35]. 
These expectations have been fulfilled in 200 human 
organ recipients trcated at the University of Pittsburgh 
[35,36··,37], including 86 who were given kidneys. The 
presence of donor a~A in myeloid and erythroid colonies 
generated from recipients' peripheral blood mononuclear 
cells as measured in standard [36.0 ] or innovative clonal 
hematopoietic progenitor cell assays [38·] has provided 
unequivocal eyidence of augmented stem-cell chimerism. 
There were no examples of significant GVH disease. 
The hypotheses of therapeutic efficacy being rested are 
that the threat of delayed (acute or chronic) rejection can 
be reduced and that the frequency of ultimate drug 
independence can be increased by the higher persistent 
level of chimerism. An efficacy evaluation is expected to 
take S to 10 vears [10·· ,3Sl, which is roughly the same 
time frame for tolerance induction learned from clinical 
experience with major histocompatibility complex-incom-
patible liver and bone marrow transplantation [100 .,34]. 
Hematolymphopoietic growth factors 
The usc of hematopoietic growth factors is another 
potential chimerism-enhancing strategy that is well 
established in bone marrow, but not in organ, transplanta-
tion. Granulocyte-macrophage colony-stimulating factor 
(Gl\1-CSF), and granulocyte colony-stimulating factor arc 
two cytokines that act at an early point in the hemato-
poietic cascade. The recently cloned Flt3 ligand [39] is 
another example. The expression of Flt3 (a member of the 
type III receptor tyrosine family) is believed to be 
restricted to primitiye progenitor cells. These cells 
respond dramatically to Flt3 ligand [39-42]' an effect that 
is increased synergistically by co-administration of colonv-
stimulating factors and c-kit ligand (stem-cell factor) [39-
42,43· ,44]. 
Administration of Flt3 ligand to normal mice leads to 
dramatic increases in DC numbers, both in lymphoid and 
in nonlymphoid tissucs [4'i]. Although DCs haye been 
implicated historically in the induction of anti-allograft 
immunity, thcy also have tolerogenic properties [460 ] and 
at the 'immaturc' precursor/progenitor stage thev mav be 
capable of subverting T-cell responses ill vitro and of 
prolonging allograft sun-ivai [47,48,49 0 .]. In contrast to the 
influence of Flt3 ligand, DCs in mouse lymphoid tissue 
are only enhanced to a moderate degree by d~l-Cpc 
[45,50]. Because numbers both of donor and of host 
hematopoietic cells of multiple lineages are increased by 
administration of GM-CSF, granulocyte colony-stimulat-
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ing factor, and FIt3 ligand, these cytokines (particularly 
Flt3 ligand) may provide a pharmacologic means of 
enhancing organ transplant chimerism. 
Predictable hazards 
As with donor leukocyte infusion, such cytokine therapy is 
expected to be safe only if both cell populations are 
subject to the same conditions of immune suppression (i.e. 
growth factor treatmcnt is started perioperatively). In 
contrast, alterations of only one of the interacting arms 
must be approached with caution, as exemplified by the 
historical experience with GVH disease after cytoablation 
and bone marrow transplantation. 'Vhen the converse 
tactic of leukocyte or T-cell specific depletion of intestinal 
allografts was attempted as GVH disease prophylaxis in 
the 1980s, virtually every bowel recipient who survived 
the perioperative period developed lethal EBV- associated 
B-ceillymphomas [51]. 
Unbalance also can be caused by delayed proVisIOn of 
donor leukocytes (e.g. repeat infusion of adjunct donor 
bone marrow to an organ recipient). To the extent that the 
first exposure (whether to infused leukocytes or to 
passenger leukocytes in a transplanted organ) induces 
tolerance, the result of the second stage delivery can 
resemble the effect of a parent to defenseless offspring Fl 
hybrid experiment. T nvestigarors signing on for multi-
center trials of serial bone marrow augmentation should be 
made aware of the consequent increased risk of GVH 
disease. 
Xenotransplantation 
Guidelines elucidated by the rwo-wa·y paradigm will 
dictate strategies of xenotransplantation. The feasibility 
of producing stable xenogeneic chimerism has been 
demonstrated in pigs given unaltered primate bone 
marrow intravenously a few hours after birth, without 
any immunosuppression [52°]. Because the primary source 
of complement is the liver, not the hematolymphopoietic 
system, it is unlikely that humoral rejection caused by the 
interspecies complement activation will he ahrogated, no 
matter what the duration of chimerism [52-]. However, by 
inducing chimerism in pigs who already have human 
complement regulatory proteins in their organs at birth, 
the barrier of complement activation and cellular tolerance 
may be jointly approach cd by clinical strategies that are 
discussed elsewhere [52°]. 
Conclusion 
The assumption that stem-cell driven hematolympho-
poietic chimerism was irrelevant to successful whole organ 
transplantation as currently practiced has led to inade-
quate explanations of organ allograft acceptance and 
clouded the meaning of successful hone marrow trans-
plantation. This has therefore precluded the development 
of a central principle of transplantation. Incorporation of 
the chimerism factor into a two-way paradigm has allowed 
previous enigmas of organ as well as bone marrow 
engraftment to be explained and should allow key 
advances in basic immunology to he more meaningfully 
exploited in transplantation, including development of 
xenotransplantation. 
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